Central Laboratories Featured Articles

  1. Are You Liable? What All Clinical Stage Companies Should Understand About Risk Disclosure 3/20/2026

    Barnes & Thornburg partner Seth Mailhot provides a primer on risk disclosure and how sponsor companies can prepare for and mitigate issues that might arise.

  2. How Important Are Medical Monitors Under ICH E6(R3)? 3/20/2026

    Discover how medical monitor-led implementation of ICH E6(R3) outperforms operations-only models across six critical performance dimensions.

  3. FDA's Elsa AI Switches From Claude To Gemini: What Sponsors Need To Know 3/12/2026

    Forced to cease using Anthropic's Claude for its Elsa generative AI assistant, the FDA is switching to Gemini. Legal experts Kimberly Chew, Esq., and Michael Yang, Esq., explain the implications for trade secrets and data security risks.

  4. When Sponsors Can't Explain How Study Data Flows, Inspection Readiness Breaks Down 3/11/2026

    Regulators want one thing during inspections — to see how the data flows, says Just In Time GCP's Donna Dorozinsky. Here, she explores the importance of data oversight and where sponsors sometimes go wrong.

  5. How Deep Learning Is Changing Clinical Trial Design, Execution, And Analysis In 2026 3/10/2026

    Deep learning is reshaping clinical trial design, execution, and analysis. Learn how to deploy it safely, measurably, and at scale with help from life sciences consultant and MIT industry advisor Partha Anbil.

  6. FDA's Draft Guidance On Bayesian Methods: Strategic Implications For Small Biotechs 3/4/2026

    The FDA draft guidance on Bayesian methodology represents a major validation of statistical innovation in clinical development. Jessica Cordes summarizes the latest from the FDA and offers advice for small biotechs.

  7. Pick The Right PV Technology With Help From A Safety Data Management Expert 2/27/2026

    Otsuka's Head of U.S. GPV Safety Data Management Vikalp Khare shares how smart governance should inform pharmacovigilance (PV) technology choices.

  8. AI Trial Matching Comes Of Age At City Of Hope 2/19/2026

    City of Hope has embedded an internally trained AI platform into oncology care and research workflows, helping clinicians summarize complex patient histories and match patients to clinical trials in real time. By reducing manual review and accelerating feasibility assessments across its national network, the system is improving trial access, easing clinician workload, and shifting more time back to patient care.

  9. 4 Factors Changing The Way CRAs Monitor Trials 1/28/2026

    The way CRAs monitor is about to change. Regeneron's Patrick Floody discusses these four factors that will influence it.

  10. Virtual Reality Endpoints Improve Measurement Of Patients' Real-World Benefit 1/12/2026

    Opus Genetics CEO George Magrath, MD, discusses how the company introduced virtual reality-enabled assessments and relied on digital endpoints to better measure participants’ vision changes.